Literature DB >> 11450719

Trabeculectomy outcomes in advanced glaucoma in Nigeria.

N Anand1, C Mielke, V K Dawda.   

Abstract

BACKGROUND: Trabeculectomy remains the mainstay of therapy for advanced glaucoma in Nigeria due to the unavailability and expense of topical therapy. Little is known of the medium- to long-term outcomes of trabeculectomy in West Africa. Purpose To retrospectively assess outcomes, in terms of lowering of the intraocular pressure and preserving the visual acuity, and the safety of trabeculectomy in patients with advanced glaucoma in Nigeria.
METHODS: A retrospective case-note search was carried out from operating theatre records in a private hospital at Lagos, Nigeria from 1989 to 1997. Patients undergoing primary trabeculectomy with a minimum follow-up of 6 months were included in the study. Visiting consultants and registrars from the UK performed the surgery. Descriptive statistics and life-table analysis were applied to the data.
RESULTS: One hundred and forty-two eyes of 100 patients were included in the study. When the criteria for success were an intraocular pressure (IOP) of less than 22 mmHg, 30% reduction from pre-operative levels and a decrease in visual acuity of less than 3 Snellen chart lines, then by life-table analysis success rates were 85%, 82% and 71% at the 1, 2 and 5 year post-operative intervals respectively. Success rates were lower if an IOP of less than 16 mmHg was taken as one of the criteria (65%, 61% and 46% at the 1, 2 and 5 year intervals, respectively).
CONCLUSIONS: Trabeculectomy without antimetabolite use appears to be an effective way to lower the IOP of advanced glaucoma patients in Nigeria to less than 22 mmHg but not to less than 16 mmHg. The procedure, in experienced hands, is relatively safe with few major complications.

Entities:  

Mesh:

Year:  2001        PMID: 11450719     DOI: 10.1038/eye.2001.93

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  11 in total

Review 1.  Glaucoma in West Africa: a neglected problem.

Authors:  Peter R Egbert
Journal:  Br J Ophthalmol       Date:  2002-02       Impact factor: 4.638

2.  Outcome of trabeculectomies without adjunctive antimetabolites.

Authors:  Me Gyasi; Wmk Amoaku; Oa Debrah; Ea Awini; P Abugri
Journal:  Ghana Med J       Date:  2006-06

3.  Deep sclerectomy and low dose mitomycin C: a randomised prospective trial in west Africa.

Authors:  C Mielke; V K Dawda; N Anand
Journal:  Br J Ophthalmol       Date:  2006-03       Impact factor: 4.638

4.  Combined Viscocanalostomy-Trabeculectomy for management of Advanced Glaucoma - A Comparative Study of the Contralateral Eye: A Pilot Study.

Authors:  Tarek M Eid; Waleed A Tantawy
Journal:  Middle East Afr J Ophthalmol       Date:  2011-10

5.  Is Beta Radiation Better than 5 Flurouracil as an Adjunct for Trabeculectomy Surgery When Combined with Cataract Surgery? A Randomised Controlled Trial.

Authors:  Kazim Dhalla; Simon Cousens; Richard Bowman; Mark Wood; Ian Murdoch
Journal:  PLoS One       Date:  2016-09-08       Impact factor: 3.240

6.  Combined Visco-Trab operation: A dual filtration pathway for management of advanced glaucoma-midterm results.

Authors:  Tarek M Eid; Ezz El-Din M Ibrahim; Ahmad Zaid
Journal:  Int Ophthalmol       Date:  2021-02-06       Impact factor: 2.031

7.  LONG TERM OUTCOMES OF AUGMENTED TRABECULECTOMY WITH 5-FLUOROURACIL IN NIGERIA.

Authors:  O O Olawoye; A O Ashaye
Journal:  J West Afr Coll Surg       Date:  2017 Jan-Mar

8.  Epidemiological properties of primary open angle glaucoma in Nigeria.

Authors:  Lawan Abdu
Journal:  J Ophthalmol       Date:  2013-05-26       Impact factor: 1.909

9.  Outcomes of trabeculectomy with 5-Fluorouracil at a nigerian tertiary hospital.

Authors:  Olusola O Olawoye; Adeyinka O Ashaye; Aderonke M Baiyeroju; Christopher C Teng; Jeffrey M Liebmann; Robert Ritch
Journal:  J Ophthalmic Vis Res       Date:  2013-04

10.  Adapted motivational interviewing to improve the uptake of treatment for glaucoma in Nigeria: study protocol for a randomized controlled trial.

Authors:  Mohammed M Abdull; Clare Gilbert; Jim McCambridge; Jennifer Evans
Journal:  Trials       Date:  2014-04-29       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.